Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (238 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: ascendingtolerabilityonset16 yearsof disease
  Phrases that lowered it: arthritisrheumatoidevaluate theto evaluatesubjects
• Sponsor's past termination rate: 15.1% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 303 (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Minimum age: 20 (lowers risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Design: single group (raises risk) · Design
• Sponsor's past trials: 485 (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports before start: 0 (raises risk) · Drug's FDA history
• Blinding: none (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis NCT00641225 · started 2008 · scored riskier than 13% of active trials completed
• Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis NCT01008852 · started 2009 · scored riskier than 98% of active trials completed
• Single Ascending Dose Study of Safety and Tolerability of Sarilumab and Methotrexate in Japanese Patients With Rheumatoid Arthritis NCT01850680 · started 2013 · scored riskier than 11% of active trials completed
• Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis NCT01414101 · started 2011 · scored riskier than 15% of active trials completed
• INCB047986 in Rheumatoid Arthritis NCT02151474 · started 2014 · scored riskier than 54% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.